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Abstract
Background: Hepatocellular carcinoma (HCC) represents a highly vascularized tumor entity and
the process of angiogenesis is essential for the growth of HCC. Importantly, the pro-angiogenic
transcription factors HIF-1α and STAT3 have been implicated in HCC progression, thus
representing interesting targets for molecular targeted therapy. We hypothesized that therapeutic
inhibition of HIF-1α could be achieved by using a novel tubulin-binding agent (ENMD-1198).
ENMD-1198 is an analog of 2-methoxyestradiol (2ME2) with antiproliferative and antiangiogenic
activity.
Methods: The human HCC cell lines HUH-7 and HepG2 were used for experiments. Effects of
ENMD-1198 on constitutive and inducible (hypoxia, growth factors) activation of signaling
cascades, including HIF-1α and STAT3, were investigated by Western blotting. Changes in VEGF
expression were determined by real-time PCR. Effects of ENMD-1198 on cancer cell migration and
invasion were evaluated in in vitro-assays. The growth-inhibitory effects of ENMD-1198 (200 mg/kg/
day) were determined in a subcutaneous tumor model (HUH-7).
Results: ENMD-1198 inhibited the phosphorylation of MAPK/Erk, PI-3K/Akt and FAK. Moreover,
activation of HIF-1α and STAT3 was dramatically reduced by ENMD-1198, which resulted in lower
VEGF mRNA expression (P < 0.05). In addition, tumor cell migratory and invasive properties were
significantly inhibited (P < 0.05, for both). In vivo, treatment with ENMD-1198 led to a significant
reduction in tumor growth, tumor vascularization, and numbers of proliferating tumor cells (P <
0.05 for all).
Conclusion: The novel microtubule destabilizing agent ENMD-1198 is suitable for inhibiting HIF-
1α and STAT3 in human HCC cells and leads to reduced tumor growth and vascularization in vivo.
Hence, inhibition of HIF-1α and STAT3 could prove valuable for therapy of hepatocellular
carcinoma.
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Background
Hepatocellular carcinoma (HCC) is the fifth most cancer
worldwide, with a continuously increasing incidence [1].
Importantly, therapy of patients with HCC remains chal-
lenging, as this tumor entity is highly resistant to systemic
therapies, and only few patients qualify for surgical or
ablative strategies due to advanced tumor stage or limited
liver function. In addition, the post-interventional relapse
rates for HCC are high, thus overall demanding the devel-
opment of novel, i.e. molecular targeted, treatment strate-
gies for improving outcome of patients with HCC.
In general, HCC represents a hypervascularized tumor
and its progression is closely related to angiogenesis [2,3].
Recent studies have not only identified the vascular
endothelial growth factor (VEGF) to be overexpressed in
hepatocellular carcinoma, but also that the transcription
factor HIF-1α plays a central role in HCC progression and
angiogenesis [4-6]. Furthermore, the transcription factor
signal transducer and activator of transcription 3 (STAT3),
yet another inducer of angiogenesis in terms of up-regu-
lating VEGF, is constitutively activated in HCC [7-9].
STAT3 has therefore drawn attention as a novel target for
cancer therapy [8,10-12]. However, development of spe-
cific inhibitors to either HIF-1α, or STAT3 has proven dif-
ficult and research is ongoing. Nevertheless, certain
compounds have lately been identified that exert an indi-
rect anti-HIF-1α activity, such as 2-methoxyestradiol
(2ME2) [13]. 2ME2 has been demonstrated to impair acti-
vation of HIF-1α through destabilization of microtubules,
in addition to exhibiting antiproliferative and pro-apop-
totic effects [13-15]. Moreover, 2ME2 has elicited growth-
inhibitory and antiangiogenic properties in preclinical
models of cancer [13,15-21] and clinical trials evaluating
2ME2 have been conducted [22-24]. However, the suita-
bility of microtubule destabilizing agents for targeting
HIF-1α in HCC has not been investigated to date.
The novel tubulin-binding compound ENMD-1198 (2-
methoxyestra-1, 3, 5, (10) 16-tetraene-3-carboxamide) is
a new chemical entity based on a modified chemical struc-
ture of 2-methoxyestradiol, which has been designed to
improve the pharmacokinetic properties, growth-inhibi-
tory, and antiangiogenic properties of 2ME2 [25]. Preclin-
ical studies identified ENMD-1198 as an orally active,
microtubule disrupting agent that leads to arrest of cell
division and apoptosis in tumor cells. Recently, ENMD-
1198 has entered a clinical phase I trial to evaluate the
safety, tolerability, pharmacokinetics, and clinical benefit
in patients with advanced cancer whose disease has failed
to respond to existing therapies.
In the current study we hypothesized that ENMD-1198
could be used to inhibit HIF-1α activation in human
hepatocellular cancer cells, which would reduce tumor
growth and angiogenesis in vivo. Importantly, since estro-
gen receptors (ER) are known to be present in advanced
HCC, the therapeutic use of an estradiol-analogons, such
as 2ME2, for antineoplastic/antiangiogenic therapy is
unknown [26-28]. Thus far, randomized controlled trials
comparing anti-estrogen therapy with conservative treat-
ment were discouraging and showed neither an antitu-
moral nor any survival benefit [27,29,30]. Importantly,
ENMD-1198 is devoid of such estrogenic effects and
therefore could offer new perspectives for therapy [25].
We therefore sought to investigate, whether ENMD-1198
is efficacious for treatment of HCC, with a particular focus
on its anti-HIF-1α and antiangiogenic potential.
Methods
Cells and culture conditions
The human hepatocellular carcinoma cell lines HUH-7
and HepG2 were obtained from the American Type Cul-
ture Collection (ATCC, Manassas, VA). Cells were cul-
tured in Dulbecco's modified Eagle's Medium (DMEM) or
RPMI1640 (Gibco, Karlsruhe, Germany) supplemented
with 10% fetal calf serum (FCS), and were maintained in
5% CO2 at 37°C. All in vitro experiments were done at
60% to 70% cell density. For in vivo experiments,
trypsinized cells were resuspended in HBSS.
Reagents and antibodies
ENMD-1198 was provided by EntreMed, Inc. (Rockville,
MD, USA) [25]. For in vitro experiments, ENMD-1198 was
dissolved in DMSO (0.1%) and equal concentrations of
DMSO served as a control in all experiments. Antibodies
against Akt, phosphorylated AktSer473, p44/42 MAPK1/2,
phosphorylated p44/42 MAPKThr202/Tyr204, signal trans-
ducer and activator of transcription 3 (STAT3), phospho-
rylated STAT3Tyr705, focal adhesion kinase (FAK) and
phosphorylated FAKTyr925 were purchased from Cell Sign-
aling Technologies (Beverly, MA). Anti-VEGF antibody
was obtained from R&D Systems (Minneapolis, MN).
Probing with an anti-β-actin antibody (Santa Cruz Bio-
technology, Santa Cruz, CA) served as a loading control.
Antibodies to HIF-1α (NB100–105) were purchased from
Novus Biologicals (Littleton, CO). Recombinant human
EGF and HGF were used in stimulation assays (R&D Sys-
tems).
MTT analysis
To evaluate cytotoxic effects of ENMD-1198 on tumor
cells, HUH-7 and HepG2 cells were seeded into 96-well
plates (1 × 103/well; 12 wells per condition) and exposed
to various concentrations of ENMD-1198 for 24 and 48
hours at 37°C. We used the methylthiazole tetrazolium
(MTT) assay to assess cell proliferation.BMC Cancer 2008, 8:206 http://www.biomedcentral.com/1471-2407/8/206
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Immunoblot analysis of constitutive and inducible signaling 
intermediates
To determine the effects of ENMD-1198 on signaling
intermediates, cancer cells were incubated for 16 hours
with FCS-RPMI containing ENMD-1198 (2,5 μM), prior
to stimulation with recombinant human EGF (40 ng/ml,
5 min and 10 min; 1% FCS-RPMI). Whole cell lysates
were prepared, as described elsewhere [31]. Protein sam-
ples (75 μg) were subjected to Western blotting on a dena-
turating 10% SDS-PAGE. Analyses for HIF-1α were
performed on both nuclear protein extracts and whole cell
lysates, as described [32]. In addition, tumor samples
were subjected to Western blotting after lysis in RIPA-B
buffer. [32,33]. Nuclear protein was extracted using a
commercially available kit (NucBuster; Novagen, Merck
Biosciences, Darmstadt, Germany). Experiments were per-
formed in triplicates and confirmed in both cell lines
(HUH-7, HepG2).
Real-time PCR analyses
For real-time PCR (RT-PCR), total RNA was isolated using
Trizol Reagent (Invitrogen, Karlsruhe, Germany) and sub-
sequently purified by ethanol precipitation. For each RNA
sample, a 1 μg aliquot was reversely transcribed into
cDNA using the Superscript II Kit (Qiagen, Hilden, Ger-
many). Primer pairs were as follows: VEGF165 (5'-GCAC-
CCATGGCAGAAGGAGGAG; 3'-
AGCCCCCGCATCGCATCAG), and ATF3 (5'-CTGCA-
GAAAGAGTCGGAG; 3'-TGAGCCCGGACAATACAC).
Primers were optimized for MgCl2 and annealing, and
PCR products were confirmed by gel electrophoresis. RT-
PCR was performed using the LightCycler system and
Roche Fast-Start Light Cycler-Master Hybridisation Probes
master mix (Roche Diagnostics, Mannheim, Germany)
[33]. Changes in VEGF-A expression were determined
after 24 and 48 hours exposure to ENMD-1198 (2.5 μM).
Enzyme-linked immunosorbent assay for VEGF protein
To determine changes in VEGF secretion by tumor cells,
we used an ELISA kit specific to human VEGF-A (Bio-
Source Europe, Nivelles, Belgium). HCC cells were plated
at 40–50% density and incubated ± ENMD-1198 (2.5 μM,
20 hours). Analyses of culture supernatants were per-
formed according to the manufacturer's protocol.
Migration and invasion assays
To determine the effect of ENMD-1198 on cancer cell
motility, migration assays were performed using modified
Boyden chambers [32]. Briefly, 1 × 105 cells were resus-
pended in 1% FCS-RPMI and seeded into inserts with 8
μm filter pores, which were either uncoated (migration
assay), or matrigel-coated (invasion assay) (Becton Dick-
inson Bioscience, Heidelberg, Germany). 1% FCS-DMEM
± EGF (40 ng/ml), or HGF (50 ng/ml), served as a chem-
oattractant. After 48 hours, cells were fixed and stained
(Diff-Quick reagent, Dade Behring, Newark, NJ) and
counted in four random fields.
Animal models
Eight-week-old male athymic nude mice (BALB/c nu/nu)
(Charles River, Germany) were used for experiments, as
approved by the Institutional Animal Care and Use Com-
mittee of the University of Regensburg and the regional
authorities. In addition, experiments were conducted
according to Guidelines for the Welfare of Animals in Exper-
imental Neoplasia published by The United Kingdom
Coordinating Committee on Cancer Research. The effects
ENMD-1198 on the growth of human hepatocellular car-
cinoma cells were evaluated in a subcutaneous xenograft
model. In brief, 1 × 106 human HCC cells (HUH-7) were
injected into the subcutis of nude mice. After implanta-
tion, tumors were allowed to grow 7 days (volume ~100
mm3) before treatment was initiated and mice rand-
omized into one of two groups (n = 10/group) receiving
either vehicle or ENMD 1198 (200 mg/kg/day) per oral
gavage. Tumor diameters were measured every other day,
and tumor volumes were calculated (width2 × length ×
0.5).
Immunohistochemical analyses of tumor vascularization 
and cancer cell proliferation
Multiple cryo-sections and paraffin-embedded section
were obtained from tumors for all immunohistochemical
analyses. CD31-positive vessel area was assessed using rat
anti-mouse CD31/PECAM-1 antibody (Pharmingen, San
Diego, CA) and peroxidase-conjugated goat anti-rat IgG
(Jackson Research Laboratories, West Grove, PA) on fro-
zen sections, as previously described [32]. Antibody bind-
ing was visualized using stable diaminobenzidine. Images
were obtained in four different quadrants of each tumor
section (2 mm inside the tumor-normal tissue interface)
at 40× magnification. Measurement of vessel area of
CD31 stained vessels was performed by converting images
to grayscale and setting a consistent threshold for all slides
using ImageJ software (version 1.33; National Institute of
Health, Bethesda, MD). Vessel areas were expressed as pix-
els per high-power field (HPF) [32]. To determine the
amount of proliferating tumor cells, mice received intra-
peritoneal injections of BrdUrd (Sigma Aldrich, Ger-
many) (1 mg/mouse) two hours prior to termination of
animal studies. A commercially available BrdUrd-detec-
tion kit (Becton Dickinson) was used to visualize BrdUrd-
uptake of cells in sections of tumors. Briefly, sections were
incubated with anti-BrdUrd antibody solution, followed
by streptavidin conjugated HRP-linked goat anti-mouse
IgG2. Antibody binding was visualized by incubating
slides in diaminobenzidine, with the aid of hematoxylin
counterstaining. BrdUrd-positive tumor cells were
counted in four fields per tumor section at 20× magnifica-
tion and averages were calculated.BMC Cancer 2008, 8:206 http://www.biomedcentral.com/1471-2407/8/206
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Statistical analysis
Results of in vivo experiments were analyzed for significant
outliers using the Grubb's test for detecting outliers http:/
/www.graphpad.com. Tumor-associated variables in in
vivo  experiments were tested for statistical significance
using the Mann-Whitney U test for non-parametric data.
The two-sided student's t-test was applied for analysis of
in vitro data. All results are expressed as the mean ± SEM.
Results
Effects of ENMD-1198 on growth of HCC cells in vitro
To determine potential cytotoxic and anti-proliferative
effects of ENMD-1198, the human hepatocellular carci-
noma cell lines HUH-7 and HepG2 were exposed to
ENMD-1198 at various concentrations (0–5 μmol/L) and
cell viability was determined by MTT analysis. Results
show, that treatment with ENMD-1198 led to a significant
dose-dependent inhibition of HCC cell growth in vitro
(Fig. 1). The IC50 (24 hours) of ENMD-1198 was seen at
2.5 μmol/L (both cell lines) and this dose was used for all
subsequent  in vitro experiments. However, this IC50
appears to be higher compared to other cell cancer cell
lines [25]. We conclude from these experiments that
ENMD-1198 elicits anti-neoplastic activity on HCC cells,
suggesting that this compound could be valuable for
reducing growth of HCC in vivo.
Effects of ENMD-1198 on cell signaling and migration of 
HCC cells
Since EGF is known to promote invasiveness and angio-
genesis of HCC [34], we first investigated whether ENMD-
1198 could be used for interfering with activation of path-
ways involved in EGF-signaling in HCC cells. Treatment
with ENMD-1198 substantially disrupted EGF signaling
in terms of diminishing downstream phosphorylation of
the substrates p44/42 MAPK and Akt (Fig. 2A). Moreover,
the activation of STAT3, an important transcription factor
for regulating VEGF-A in cancer cells, was markedly
reduced by ENMD-1198 (Fig. 2A, B). In addition, an EGF-
induced phosphorylation of FAK, yet another essential
mediator for cancer cell invasiveness, was markedly inhib-
ited by ENMD-1198 (Fig. 2A). As a functional conse-
quence of multiple signaling pathway inhibition and
interference with transcriptional regulation, ENMD-1198
significantly inhibited both EGF- and HGF-mediated can-
cer cell migration and invasiveness (Fig. 3A, B). These
experiments suggest that ENMD-1198 may effectively
interfere with crucial EGF-mediated and angiogenesis-
related signaling cascades in hepatocellular carcinoma
cells. Hence, treatment with ENMD-1198 may not only
Antiproliferative effects of ENMD-1198 on HCC cells Figure 1
Antiproliferative effects of ENMD-1198 on HCC cells. 
HUH-7 cells were incubated for 24 h with various concentra-
tions of ENMD-1198 and MTT reading was performed there-
after. ENMD-1198 dose-dependently elicited significant 
antiproliferative effects on HCC cells with an IC50at 2.5 μM 
in both cell lines (data shown for HUH-7) (*P < 0.05). Bars 
represent mean ± SEM from three independent experiments. 
Bars: SEM.
Effect of ENMD-1198 on signaling in HCC cells Figure 2
Effect of ENMD-1198 on signaling in HCC cells. West-
ern blot analysis was performed to determine signaling path-
ways affected by therapy with ENMD-1198. Recombinant 
EGF (40 ng/ml) was used for stimulating cells after pre-incu-
bation with ENMD-1198 (16 hours). A) HUH-7 cells and B) 
HepG2 cells were used for experiments. ENMD-1198 abro-
gated EGF-induced phosphorylation of Akt (HUH-7), FAK 
(HUH-7), p44/42 MAPK (HepG2), and STAT3 (HUH-7, 
HepG2). β-actin served as a loading control.BMC Cancer 2008, 8:206 http://www.biomedcentral.com/1471-2407/8/206
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Impact of ENMD-1198 on cancer cell migration and invasion Figure 3
Impact of ENMD-1198 on cancer cell migration and invasion. The effects of ENMD-1198 on cancer cell migration 
were determined by using modified Boyden chambers. A) In migration assays (HUH-7), ENMD-1198 (2.5 μM) effectively 
reduced cancer cell motility and blunted the response to either EGF, or HGF (*P < 0.01). B) The effects on cancer cell invasive-
ness were evaluated using Matrigel-coated inserts. ENMD-1198 (2.5 μM) significantly abrogated EGF- and HGF-mediated inva-
sive properties of hepatocellular carcinoma cells, compared to controls (*P < 0.01 for all). Experiments were performed in 
triplicates and results were confirmed in a second cell line (HepG2). Bars: SEM.
affect tumor angiogenesis, but also harbors the potential
to reduce metastasis through diminishing migratory and
invasive properties of HCC cells.
Effects of ENMD-1198 on nuclear HIF-1α expression and 
VEGF expression
The transcription factor HIF-1α has been identified as an
important promoter of HCC growth and angiogenesis
[4,35]. Importantly, the ability of ENMD-1198 and 2ME2
to inhibit HIF-1α has recently been suggested in preclini-
cal tumor models of solid malignancies [13,14]. We there-
fore investigated whether ENMD-1198 could also
interfere with hypoxia-induced signaling in human hepa-
tocellular carcinoma cells. Western blotting showed that
treatment with ENMD-1198 markedly diminished a
hypoxia-induced (1% O2) activation of HIF-1α in cancer
cells (Fig. 4A). As HIF-1α is an important regulator of the
pro-angiogenic molecule VEGF [36], we next determined
the effects of ENMD-1198 on VEGF-A expression in HCC
cells by real time PCR. Results show that treatment with
ENMD-1198 slightly reduced constitutive (non-hypoxic)
VEGF-A mRNA expression levels in HCC cells, though
results were statistically significant (Fig. 4B). Similar mod-
est effects of ENMD-1198 on VEGF protein were seen in
an ELISA assay (Fig. 4C) and Western blot (Fig. 4D) under
hypoxic conditions (20 h, 1% O2) in vitro. However, HCC
cells in general expressed only low levels of VEGF in in
vitro conditions, suggesting that other angiogenic factors
may also be involved in tumor angiogenesis of these
tumor cells when growing in vivo. We conclude from these
experiments that treatment with ENMD-1198 effectivelyBMC Cancer 2008, 8:206 http://www.biomedcentral.com/1471-2407/8/206
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Effect of ENMD-1198 on HIF-1α and VEGF expression in HCC cells Figure 4
Effect of ENMD-1198 on HIF-1α and VEGF expression in HCC cells. To determine effects of ENMD-1198 on nuclear 
HIF-1α expression, HUH-7 cells were incubated for 16 h ± ENMD-1198 and subsequently exposed to hypoxia (1% O2, 4 h). A) 
Western blot analysis of whole protein showed that ENMD-1198 effectively blunted hypoxic induction of HIF-1α protein. B) In 
addition, treatment with ENMD-1198 down-regulated constitutive VEGF-A mRNA levels in HCC cells (HepG2), as measured 
by real-time PCR (* P < 0.01) (n = 3/group). VEGF-A mRNA expression is normalized to β-actin. C) ELISA analysis for VEGF in 
culture supernatants (HepG2). Hypoxia (20 h, 1% O2) markedly increased VEGF protein. ENMD-1198 treatment lowered 
VEGF secretion under hypoxic conditions (*P < 0.05). D) Western blot analysis for VEGF. Cells were incubated under either 
non-hypoxic, or hypoxic conditions ± ENMD-1198. Treatment with ENMD-1198 slightly lowered the hypoxic induction of 
VEGF, as determined by densitometry. Bars: SEM.BMC Cancer 2008, 8:206 http://www.biomedcentral.com/1471-2407/8/206
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Effect of ENMD-1198 on growth of colorectal cancer cells in vivo Figure 5
Effect of ENMD-1198 on growth of colorectal cancer cells in vivo. To determine growth-inhibitory effects of ENMD-
1198 in vivo, HUH-7 cells were implanted subcutaneously into mice (n = 10/group) which received either ENMD-1198 (200 mg/
kg/day) or diluent when tumors became palpable. A) Treatment with ENMD-1198 led to a significant growth inhibition of 
xenografted hepatocellular tumors, compared to controls (*P < 0.05). B) Final tumor weights (day 19) in the ENMD-1198 
treatment group were significantly lower, compared to excised tumors of the control group (*P < 0.05). Bars: mean ± SEM.
disrupts hypoxic signaling in HCC cells which is mediated
through HIF-1α.
Effects of ENMD-1198 on growth and vascularization of 
hepatocellular carcinoma in vivo
To estimate growth inhibitory and antiangiogenic effects
of ENMD-1198 in vivo, we used a subcutaneous tumor
model (HUH-7 cells). Treatment with ENMD-1198 (200
mg/kg/day) significantly reduced growth of HUH-7
tumors, compared to controls (Fig. 5A). This reduction in
tumor growth was also reflected by final tumor weights of
excised tumors on day 19, which were significantly lower
in the ENMD-1198 treatment group (Fig. 5B). Impor-
tantly, mouse body weights did statistically not differ
among these two groups (controls: 22.1 ± 0.7; ENMD-
1198: 20.3 ± 0.9 [mean ± SEM]; P = 0.15). Furthermore,
vascularization of HUH-7 tumors in terms of CD31-posi-
tive vessel area was significantly reduced in tumor sections
of the ENMD-1198 group (Fig. 6A). Moreover, treatment
with ENMD-1198 also reduced the number of proliferat-
ing (BrdUrd-positive) tumor cells (Fig. 6B). Importantly,
Western blotting of tumor tissues showed markedly
decreased HIF-1α expression in ENMD-1198 treated
tumors, suggesting that this target is inhibited in vivo (Fig.
6C). In conclusion, these experiments demonstrate that
ENMD-1198 effectively inhibits growth of hepatocellular
carcinoma through direct effects on the tumor cells, and
also through inhibition of angiogenesis.
Discussion
The present study shows that the 2ME2-analog ENMD-
1198 interferes with growth factor-induced signaling in
hepatocellular carcinoma and effectively inhibits HIF-1α
and STAT3 activation. This disruption in cell signalingBMC Cancer 2008, 8:206 http://www.biomedcentral.com/1471-2407/8/206
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Effect of ENMD-1198 on tumor vascularization and tumor cell proliferation Figure 6
Effect of ENMD-1198 on tumor vascularization and tumor cell proliferation. A) Immunohistochemical analysis of 
tumor vascularization (CD31-positive vessels). Densitometric analysis of images from CD31-stained tissue sections from all 
tumors showed that vessel area was significantly reduced in ENMD-1198-treated tumors (*P < 0.01). B) ENMD-1198 signifi-
cantly decreased the number of proliferating (BrdUrd-positive) tumor cells in tissue sections (*P < 0.01). For both vessel area 
and cell proliferation, representative images are illustrated. Results shown are the mean ± SEM. C) Western blot analysis for 
HIF-1α expression in HCC tumors showed a substantial reduction of HIF-1α in ENMD-1198 treated tumors.BMC Cancer 2008, 8:206 http://www.biomedcentral.com/1471-2407/8/206
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leads to a significant reduction of migratory and invasive
properties of cancer cells and diminishes VEGF mRNA
expression.
Tissue hypoxia constitutes as one of the main characteris-
tics of the tumor microenvironment and has been shown
to be implicated in the progression and metastasis of var-
ious solid malignancies [37-39]. One key regulatory pro-
tein in the cell response to changing oxygen levels is the
hypoxia inducible factor-1α (HIF-1α). Interestingly, HIF-
1α activation appears to be a very early event in carcino-
genesis and this protein is expressed before histological
evidence of angiogenesis or invasion even occur [40]. In
regards to HCC, overexpression of HIF-1α has been
reported, which has been associated with a poor progno-
sis [41-43]. Recently, both HIF-1α and VEGF were identi-
fied to be involved in the malignant transformation of
dysplastic liver nodules and additionally a hypoxia-inde-
pendent overexpression of HIF-1α has been shown to be
involved in a model of mouse hepatocarcinogenesis
[4,35]. Overall, these studies suggest that anti-HIF-1α
therapy could prove valuable for treatment of HCC, or its
pre-malignant lesions. However, specific inhibitors to
HIF-1α are still under development, thus demanding the
evaluation of alternative strategies for inhibiting HIF-1α
in cancers. Interestingly, recent studies have demonstrated
that 2ME2, an endogenous metabolite of estrogen, elicits
antineoplastic efficacy which in part is mediated by an
anti-HIF-1α activity [13,14]. The substance used in our
study, ENMD-1198, is based on a modified chemical
structure of 2ME2. However, ENMD-1198 has previously
been evaluated in models of HCC. Indeed, we now dem-
onstrate that ENMD-1198 effectively inhibits activation of
HIF-1α in HCC, ultimately leading to a reduction of
tumor growth and vascularization in vivo. However, the
exact mechanism by which 2ME2 and ENMD-1198
inhibit HIF-1α is not fully understood. Recent studies sug-
gested that 2ME2 treatment induces superoxide radicals in
tumors [44,45], which in turn could down-regulate HIF-
1α. Another potential mechanism for reducing HIF-1α
activity could be mediated through interference with
STAT3 phosphorylation, as STAT3 is required for forming
an active HIF-1 complex [46]. In HCC, STAT3 appears to
play a central role, as this transcription factor is implicated
in oncogenesis and metastasis [7,9,12]. Furthermore,
STAT3 appears to be necessary for a PI-3K/Akt-mediated
hypoxia-independent HIF-1α protein synthesis [46,47].
Importantly, our results indicate that ENMD-1198 effec-
tively diminishes phosphorylation of STAT3 in HCC cells,
a finding which has not been reported for 2ME2 com-
pounds to date. Hence, we now provide evidence for
another mechanism for impairing HIF-1α function in
cancer cells by 2ME2-like inhibitors in terms of diminish-
ing STAT3 activation. Moreover, ENMD-1198 also
reduced phosphorylation of Akt, a signaling intermediate
that is up-stream of HIF-1α, thus resulting in further
impairment of HIF-1α activity. This was also reflected in
Western blot results for HIF-1α expression analysis in
tumor tissues, which were markedly reduced in the
ENMD-1198 treated tumors. In fact, one has to realize
that tumor sizes differ significantly among these treat-
ment groups, which per se could affect HIF-1α expression.
Nevertheless, we also detected a diminished STAT3 activa-
tion by Western blotting of tumor tissues in the ENMD-
1198 treatment group (data not shown), suggesting that
the drug also effectively inhibits both targets in vivo.
Another important aspect is the observed anti-metastatic
property of ENMD-1198 in vitro, as treatment of HCC cells
led to reduced phosphorylation of the pro-migratory sig-
naling component FAK. In in vitro assays, ENMD-1198
substantially abrogated EGF- and HGF-mediated cancer
cell migration and invasiveness, suggesting that this sub-
stance could be valuable for reducing HCC metastasis.
Development of intra-hepatic metastases is a common
problem in HCC patients who underwent liver resection
for HCC, or are on the waiting list for transplantation.
Since HIF-1α and STAT3 both promote metastasis forma-
tion, treatment with ENMD-1198 appears to be reasona-
ble and warrants further investigation. ENMD-1198 is
already being investigated in a phase I trial in advanced
cancers and results from these trials will be important for
further defining the suitability of this agent in cancer ther-
apy.
Conclusion
In conclusion, our study demonstrates that treatment
with ENMD-1198 harbors significant potential for reduc-
ing growth and vascularization of hepatocellular carci-
noma. Importantly, ENMD-1198 effectively diminishes
both HIF-1α and STAT3 activation in HCC cells, which
represent important mediators of HCC progression. Our
data are therefore in favor of evaluating this concept of tar-
geting microtubules in clinical trials for therapy of human
hepatocellular carcinoma.
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